Flupenthixol + Melitracen is a fixed-dose combination (FDC) of a thioxanthene neuroleptic (Flupenthixol) and a tricyclic antidepressant (Melitracen). It is primarily used for the treatment of mixed anxiety-depressive disorders, dysthymia, and psychosomatic disorders. The combination is designed to provide a balanced effect, where Flupenthixol elevates mood and reduces anxiety, while Melitracen provides antidepressant and anxiolytic effects. It is a widely prescribed psychotropic medication in the Indian outpatient setting for mild to moderate neurotic conditions.
Adult: One tablet (Flupenthixol 0.5 mg + Melitracen 10 mg) twice daily, usually morning and afternoon. In milder cases, one tablet once daily (morning) may suffice. Maximum: 3 tablets per day.
Note: Administer orally with or after food to minimize gastric upset. The last dose should not be taken too late in the evening to avoid potential sleep disturbances due to the activating effect of Flupenthixol. Tablet can be split for dose titration. Do not crush or chew unless scored.
The combination works via complementary mechanisms. Flupenthixol is a potent dopamine D1 and D2 receptor antagonist, which at low doses modulates dopaminergic neurotransmission, leading to mild antipsychotic, mood-stabilizing, and activating effects. Melitracen is a tricyclic antidepressant that primarily inhibits the reuptake of noradrenaline (norepinephrine) and, to a lesser extent, serotonin in the presynaptic neurons, thereby increasing their synaptic concentrations. The net effect is an improvement in mood, reduction in anxiety and psychomotor retardation, without significant sedation at standard doses.
Pregnancy: Category C (US FDA). Risk cannot be ruled out. Animal studies show adverse effects. Use only if potential benefit justifies potential fetal risk. Neonates exposed in the 3rd trimester may experience withdrawal symptoms (irritability, hypertonia) or anticholinergic effects. Avoid use, especially in the first trimester.
Driving: May impair alertness, reaction time, and motor coordination, especially during initial therapy or dose changes. Patients should be cautioned against driving or operating heavy machinery until their individual response is known.
| Monoamine Oxidase Inhibitors (MAOIs) - e.g., Phenelzine, Selegiline | Risk of hypertensive crisis, serotonin syndrome, hyperpyrexia. | Contraindicated |
| Other CNS Depressants (Alcohol, Benzodiazepines, Opioids) | Additive CNS depression, impaired alertness, respiratory depression. | Major |
| Anticholinergic drugs (e.g., Atropine, Trihexyphenidyl, TCAs) | Increased risk of severe anticholinergic effects (ileus, hyperthermia, confusion). | Major |
| Antihypertensives (especially Alpha-blockers, Guanethidine) | Potentiated hypotensive effect, risk of severe orthostasis. | Moderate |
| QT-prolonging drugs (e.g., Class IA/III antiarrhythmics, Macrolides, Fluoroquinolones) | Additive risk of QT prolongation and torsades de pointes. | Major |
| SSRIs/SNRIs (e.g., Fluoxetine, Sertraline, Venlafaxine) | Increased serotonergic activity, risk of serotonin syndrome. | Moderate |
| Enzyme Inducers (e.g., Carbamazepine, Phenytoin, Rifampicin) | Reduced plasma levels of both Flupenthixol and Melitracen, decreasing efficacy. | Moderate |
| Enzyme Inhibitors (e.g., Fluoxetine, Paroxetine, Cimetidine) | Increased plasma levels, risk of toxicity. | Moderate |
| Sympathomimetics (e.g., Adrenaline, Noradrenaline) | Exaggerated pressor response, arrhythmias. | Moderate |
| Levodopa and Dopamine Agonists | Antagonized therapeutic effect in Parkinson's disease. | Major |
Same composition (Flupenthixol (NA) + Melitracen (NA)), different brands: